💊 의약품 A-Z 🧬 표적 🛠 도구 📚 가이드
전체 의약품 약물 분류 치료 영역 부작용
가이드 용어집 연대표
비교 약물 체내 여정 약물 계열
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Warfarin Sodium

CHEMBL1200879 Phase 4 승인됨 Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
330.3 g/mol
LogP
—
Phase
4

A sodium salt form of warfarin with the same therapeutic properties. This anticoagulant (blood thinner) medication is used to prevent and treat blood clots, including those in deep veins (DVT), the lungs (pulmonary embolism), and to reduce the risk of stroke in patients with atrial fibrillation or artificial heart valves.

분자량

330.3000 g/mol

TPSA

66.40 Ų

치료 영역

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Endometriosis Cardiovascular Disease Pain Management Non-Small Cell Lung Cancer Rheumatoid Arthritis Osteoporosis Chronic Obstructive Pulmonary Disease Alzheimer's Disease Parkinson's Disease Epilepsy Migraine Schizophrenia Bipolar Disorder Generalized Anxiety Disorder Insomnia Melanoma Psoriasis Systemic Lupus Erythematosus Multiple Sclerosis Chronic Kidney Disease Stroke Deep Vein Thrombosis / Pulmonary Embolism Obesity Lymphoma Type 2 Diabetes Hypertension Major Depressive Disorder Breast Cancer Atopic Dermatitis Chronic Pain Heart Failure Atrial Fibrillation Prostate Cancer Colorectal Cancer

작용 기전

Inhibits vitamin K epoxide reductase complex.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

기전

Inhibits vitamin K epoxide reductase complex.

2D 구조

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CC(=O)CC(c1ccccc1)c1c([O-])c2ccccc2oc1=O.[Na+]

                

                

                
                

                    
InChI

                    
InChI=1S/C19H16O4.Na/c1-12(20)11-15(13-7-3-2-4-8-13)17-18(21)14-9-5-6-10-16(14)23-19(17)22;/h2-10,15,21H,11H2,1H3;/q;+1/p-1

                

                

                

                    
                    

                        
Molecular Formula

                        
C19H15NaO4

                    

                    
                    

                        
HBD / HBA

                        
- / 4

                    

                    
                    

                        
회전 가능 결합

                        
4

                    

                    
                    
                    

                        
무거운 원자

                        
24

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
자주 묻는 질문

                

                    
                    

                        
                        

                            
A sodium salt form of warfarin with the same therapeutic properties. This anticoagulant (blood thinner) medication is used to prevent and treat blood clots, including those in deep veins (DVT), the lungs (pulmonary embolism), and to reduce the risk of stroke in patients with atrial fibrillation or artificial heart valves.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Inhibits vitamin K epoxide reductase complex.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Warfarin Sodium is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL1200879.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 16204922.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
의학적 면책조항

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.